AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01979731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guidelines ergonomics
Description: Orientation about manual material handling, posture, furniture, rest break and others in general.
Study NCT03032354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12
Description: Combination therapy of probiotics during 6 months
Study NCT03032354 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, (Placebo group)
Description: Placebo during 6 months
Study NCT03763955 — intervention group
Intervention type: BEHAVIORAL
Intervention: MIRT
Description: 4 week MIRT provide:~1. front to front treatment (1 hour/day for 5 days/week)~2. treatment with robotic devices (1 hour/day for 5 days/week)~3. occupational therapy (1 hour/day for 5 days/week)
Study NCT03626441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger
Study NCT03626441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger.
Study NCT03626441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger.
Study NCT02403843 — intervention group
Intervention type: DEVICE
Intervention: RNS System
Description: The RNS System provides closed loop responsive brain stimulation. In response to detection of previously identified electrocorticographic activity, the neurostimulator delivers stimulation to the seizure foci by way of the leads to interrupt the activity before the patient experiences clinical seizures. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
Study NCT00601003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox
Description: 30mg/kg/day PO divided into TID dosing q day
Study NCT00601003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m2/dose in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
Study NCT00601003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 0.75mg/m2/dose, in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
Study NCT02708433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine
Study NCT01654081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
Study NCT03729024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Adjustable lens (LAL) and Light Delivery Device (LDD)
Description: Primary and Fellow eyes will receive Light adjustable lens with Light delivery Device treatments
Study NCT03203694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking: Intervention arm in diabetics
Description: The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
Study NCT03203694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking: No intervention in diabetics
Description: Subjects will be instructed to continue their usual lifestyle for 8 weeks.
Study NCT03203694 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Walking: Healthy cohort as reference controls
Description: Subjects will be studied at one time only.
Study NCT03203694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower body heating: Intervention arm in healthy subjects
Description: This intervention consists of 60 minutes of lower body heating (40-42 degree C).
Study NCT03203694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower body heating: Intervention arm in diabetics
Description: This intervention consists of 60 minutes of lower body heating (40-42 degree C) 7 days per week for 7 days.
Study NCT03203694 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lower body heating: Healthy cohort as reference controls
Description: Subjects will be studied at one time only.
Study NCT02430363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK - 3475
Description: Administered Intravenously
Study NCT02430363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Suppressor of the PI3K/Akt pathways
Description: Capsules orally with food
Study NCT01720784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alginate dietary fiber
Study NCT01720784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02122653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight training
Description: Participants will perform 4 weeks of Weight training for lower extremities.
Study NCT01171703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
Study NCT01717482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT01717482 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Standard of Care Observation
Study NCT01675570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10045
Description: One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
Study NCT01675570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle for RX-10045
Description: One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
Study NCT00782184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40
Description: ezetimibe/simvastatin 10/40 tablet once daily for 6 weeks.
Study NCT00782184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin 40 mg
Description: atorvastatin 40 mg tablet once daily for 6 weeks
Study NCT00782184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin 20 mg
Description: All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization
Study NCT00782184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin 20 mg
Description: All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization
Study NCT01072435 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled sedation
Description: Administration of short-acting anesthetic propofol via self-administration device.Single bolus-dose 1ml(10mg)of propofol,lockout time 0sec.,no background infusion or dose-limit.
Study NCT01072435 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Target-controlled infusion
Description: Anaesthesiologist´s managed target-controlled infusion of short-acting anesthetic propofol
Study NCT01921790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin 7.5mg/Kg, intravenous drip D1
Study NCT01921790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1g/m2 intravenous drip D1,D8
Study NCT01921790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2 intravenous drip D1
Study NCT01921790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Pegaspargase 2500U/m2 intramuscular injection (IM) D1
Study NCT01921790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20mg/d intravenous drip D1, po D2-3
Study NCT02122653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic muscle stimulator
Description: Participants will perform 4 weeks of electrical stimulation for Quadriceps muscle belly.
Study NCT02736968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auranofin
Description: Auranofin is a gold-containing chemical salt available as 3mg capsules
Study NCT02736968 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00628914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram and eszopiclone
Description: escitalopram 10mg tabs QD and eszopiclone 3 mg tabs QD for 8 weeks
Study NCT00628914 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram, eszopiclone, and placebo
Description: Escitalopram 10mg tabs QD for 8 weeks; Eszopiclone 3mg tabs QD for initial 4 weeks then placebo tabs QD for final 4 weeks
Study NCT00628914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10mg tabs QD and placebo tabs QD for 8 weeks
Study NCT04318093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Specified dose on specified days
Study NCT02899481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transabdominal and transperineal ultrasound
Description: Transabdominal ultrasound, for determining fetal head position, is performed with the pregnant women in supine position after bladder emptying, with the transducer placed transversely on the suprapubic region of the maternal abdomen. For the sonographic determination of the fetal descent we will perform a transperineal ultrasound achieved by placing the ultrasound transducer on the perineum in a mid sagittal position between the labia below the pubic symphysis.
Study NCT04318093 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT02998021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Dumbbell
Description: Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks. The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively, first by increasing the frequency of the vibration (max. 40 Hz) then by the addition of more weight, based on weekly assessments and consultation with the senior investigators.
Study NCT02998021 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dumbbell
Description: Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks.~The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively by the addition of more weight, based on weekly assessments and consultation with the senior investigators.~To obtain as much data as possible on resistance training with vibration within study timeline, a modification was recently approved by the Institutional Review Board (IRB) to cease enrolling subjects into standard dumbbell training.
Study NCT02973555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: autologous intrauterine infusion of PRP
Study NCT02057003 — intervention group
Intervention type: DRUG
Intervention: DAA against HCV
Study NCT01695733 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent influenza vaccine
Study NCT05031676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: opioid free anesthesia
Description: Maintenance of anesthesia was done with halothane. The incision was allowed at 1.2 MAC of halothane. This halogen was administered according to the hemodynamic parameters and the habits of the anesthesia team. Before waking up, all the patients benefited from preventive analgesia with 1 g paracetamol combined with 20 mg nefopam by slow intravenous injection over approximately 15 minutes.
Study NCT03150927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Microbial Composite
Description: 125mg (or 250 mg) of BiOWiSH Probiotic Microbial Composite™ is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
Study NCT03150927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 125mg (or 250 mg) of Placebo is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
Study NCT03100994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: injecting anesthetics to different local
Study NCT03100994 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound guided nerve block
Study NCT01476488 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: tacrolimus
Study NCT04723849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Auxilie® Immuplus, Envicon Medical, Verona, Italy
Description: Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study. Height (cm) and weight (kg) were measured for each child at every visit. Endothelial function was assessed using two methodologies: a post occlusive release hyperemic test (PORH) and a heat provocation test (HPT).
Study NCT04723849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Auxilie® Immuplus, Envicon Medical, Verona, Italy
Description: Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study. Height (cm) and weight (kg) were measured for each child at every visit. Endothelial function was assessed using two methodologies: a post occlusive release hyperemic test (PORH) and a heat provocation test (HPT).
Study NCT02844491 — intervention group
Intervention type: OTHER
Intervention: additional biological samples
Description: blood and tissue samples
Study NCT00610064 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Baseline neuroimaging
Description: Baseline neuroimaging using PET and MRI of the brain in patients before sacral neuromodulation
Study NCT00610064 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Neuroimaging during sacral neuromodulation
Description: Neuroimaging during sacral neuromodulation using PET
Study NCT01283321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human fibrinogen concentrate
Description: 4 g IV once, within 30 minutes of ACT \< 155 seconds, post CPB, with evidence of significant microvascular bleeding
Study NCT01283321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: apheresis platelets
Description: A single apheresis platelet unit will be administered as an initial therapy within 30 minutes of ACT \<155 seconds post CPB with evidence of significant microvascular bleeding.
Study NCT01928680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Capecitabine
Description: Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity
Study NCT02751463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunscreening Sport Spray Rest (BAY987519)
Description: 50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.(Formulation Number - RB# Y51-002 )
Study NCT02751463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated skin
Description: One site is patched without treatment as control
Study NCT02044458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stylette
Description: use of stylette for successful insertion of foley catheter for induction of labor
Study NCT01656928 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: preschool-based nutritional intervention
Description: 6-month intervention administered once weekly by a nutrition expert consisting of joint meal preparation and activities for children and parents such as tasting and preparing nutritious, fresh foods.
Study NCT01656928 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: preschool-based nutritional intervention
Description: 6-month intervention administered once weekly by a nutrition expert consisting of joint meal preparation and activities for children and parents such as tasting and preparing nutritious, fresh foods.
Study NCT03104647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VRP-Clinic
Description: Subjects will perform a series of neck movements guided by graphic instructions appearing in the virtual reality environment
Study NCT02493049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Addition of Domperidone to current Disease Modifying Therapy.
Study NCT03768765 — intervention group
Intervention type: PROCEDURE
Intervention: Holmium Laser Prostate Surgery
Description: Patients will undergo standard of care holmium laser prostate surgery
Study NCT03539770 — intervention group
Intervention type: PROCEDURE
Intervention: Posterior spinal fusion
Description: Surgical procedure that involves placement of spinal rods to correct spinal curvature
Study NCT04612855 — intervention group
Intervention type: OTHER
Intervention: Groupwise comparison of primary and secondary outcomes
Description: Statistical comparison of cohorts. Cfr supporting information on statistical plan.
Study NCT04104724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help
Description: self-help materials - cognitive behavioural and compassion-focused; psychoeducation, practical help re. attending cervical cancer screening
Study NCT02134249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmin
Description: 2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for14 days
Study NCT02134249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: 1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
Study NCT00978250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
Description: FdCyd, a fluoropyrimidine nucleoside analog, has a short (10-minute) half-life and is rapidly degraded in vivo by cytidine deaminase. However, co-administration with THU, an inhibitor of cytidine/deoxycytidine deaminase, has been shown to increase the area under the curve (AUC) of the parent compound more than 4-fold. Increased FdCyd exposure allows it to be taken up intracellularly and converted to its triphosphate, which is incorporated into deoxyribonucleic acid (DNA) and inhibits the action of the enzyme DNA methyltransferase (DNMT). Inhibition of DNMT, and in turn DNA methylation, can result in the re-expression of tumor suppressor genes.
Study NCT03912649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RemovAid
Description: The RemovAid device is used for removal
Study NCT00166361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Memokath 051 Ureteral Stent
Description: The Memokath 051 ureter stent is used for the treatment of malignant or benign ureteric strictures in both men and women. The stent design consists of a tightly-coiled nickel-titanium alloy, with a diameter of 10.5 French (Fr) and a fluted proximal diameter expanding to 22 Fr. The stent is manufactured in multiple lengths which are chosen to position the device across the narrowed area rather than crossing the ureteropelvic or ureterovesical junction. It has a thermal memory system for its predetermined shape; the stent softens at temperatures below 10 degrees Celsius but regains its shape when heated above 55 degrees Celsius.
Study NCT00166361 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JJ Stent
Description: A JJ stent is a flexible plastic tube that drains urine from the kidney to the bladder and is supposed to stay in place temporarily. There is a coil on each end to keep the stent in place, preventing the stent from migrating down and out from the kidney or up from the bladder into the ureter. The stent can stay in place for few weeks to 3 months or more depending on the indication. If left for more than 6-9 months some stents may get encrusted leading to stone formation around the stent.
Study NCT00240682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Dosage form: bottles of 50 ml, 2 mg/ml; Dosage:400 mg/m2 initial dose followed by 250 mg/m2 by infusion every week; Number of Cycles : until progression or unacceptable toxicity develops.
Study NCT02661802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen Supplementation
Description: Oxygen delivery was continuous by mask at 40%